
P/E Ratio: Price to Earnings - Most used valuation metric
Analyzing Investment Quality
Processing 9 key metrics...
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Loading shareholding data...
No insider trading data available
Standard pivot points - most widely used
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹18.00 | +₹4.09 | +29.43% |
| R3 | ₹16.46 | +₹2.55 | +18.36% |
| R2 | ₹15.94 | +₹2.03 | +14.57% |
| R1 | ₹14.92 | +₹1.01 | +7.28% |
| PIVOT | ₹14.40 | 0.49 | 3.50% |
| CURRENT | ₹13.91 | - | - |
| S1 | ₹10.30 | -₹3.61 | -25.93% |
| S2 | ₹11.84 | -₹2.07 | -14.86% |
| S3 | ₹12.86 | -₹1.05 | -7.57% |
| S4 | ₹13.38 | -₹0.53 | -3.79% |
is trading CPR, indicating
CPR is
Day's range: ~
Trading Inside opening range
No peer comparison data available

Ortin Global Limited is a pharmaceutical company based in Hyderabad, India, established in 1986 and rebranded in June 2024. Its primary business revolves around the manufacture and trade of pharmaceuticals, drugs, and their intermediate components within the Indian market and potentially for export.
The company operates through two main segments: manufacturing and trading. The manufacturing segment focuses on a wide array of pharmaceutical formulations, encompassing various therapeutic categories. These include tablets, capsules, syrups, and dry powders targeting conditions such as diabetes, allergies, cardiovascular issues, infections (bacterial, fungal, parasitic), pain, and gastrointestinal problems. Their product portfolio also extends to psychiatric medications, nutritional supplements (vitamins, proteins, enzymes), and anti-retroviral drugs.
Beyond finished formulations, Ortin Global also manufactures active pharmaceutical ingredients (APIs) and their intermediates. This vertical integration allows them to control a significant portion of their supply chain. The APIs manufactured include those used in anti-retrovirals, diabetes treatments, pain relievers, antibiotics, antifungals, antacids, and anti-malarial drugs. They also produce fine chemicals and organometallic compounds like Grignard reagents.
Complementing its manufacturing capabilities, Ortin Global provides a range of research and development services. These services encompass process development and optimization, product characterization, analytical testing (assay development), and formulation development for new brands. Furthermore, they offer diagnostic services including the development of rapid diagnostic kits and reagents. The company also undertakes long-term contracts for the custom manufacturing of intermediates and the development of new APIs.
In addition to its core pharmaceutical operations, Ortin Global engages in the export of finished pharmaceutical formulations and holds real estate assets. The company’s diversified business model combines manufacturing, trading, research and development, and real estate holdings, contributing to its overall revenue streams.
Mayfair Gardens, 8-2-682/3/A & 3B, Flat No. 201, 2nd Floor, Road No.12, Banjara Hills
Hyderabad
TELANGANA
IN
Tel: 914027562055
Website:https://www.ortinlabsindia.com/
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
0IPO Date: 15/11/1996
Get answers to the most common questions about Ortin Global Ltd stock price, fundamentals, financial metrics, and investment analysis